Great Partnerships Enable Greater Solutions
Our partnerships help us offer next-level solutions so we continue to lead the industry with an innovative approach to going label-free. Find out how our partnerships are helping us set a gold standard at SAMDI Tech.
The mission of the National Cancer Institute’s Experimental Therapeutics Program (NExT) is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. SAMDI Tech’s label-free assay platform is an important tool in the NExT pipeline for the discovery of novel small molecule inhibitors for next generation cancer targets.
Aptuit provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry. SAMDI Tech and Aptuit’s partnership broadens the portfolio of assay development and high-throughput drug discovery services in Europe and North America, providing early stage drug discovery researchers access to SAMDI Tech’s unique label-free platform as well as Aptuit’s lead-like small molecule compound libraries.
Confluence Discovery Technologies delivers custom research solutions, specializing in complex biological systems, challenging drug target inhibitory mechanisms and preclinical and clinical biomarker development. Through this partnership, SAMDI Tech and Confluence offer a range of services from drug discovery to preclinical development, combining their expertise to provide a comprehensive solution from HTS and follow-up through structure-based drug design, cell-based assays and in vivo pharmacology.